Posted: Thursday, February 6, 2025
Daniela E. Matei, MD, of Northwestern Medicine, Feinberg School of Medicine, discusses the currently known targets of biology-driven therapy for ovarian cancer and several of the ongoing trials of newer agents that may ultimately impact the clinical care of patients with this type of gynecologic cancer in the future.